This rapid review aims to synthesise recommendations and statements from international clinical guidelines, consensus statements, and position statements regarding the medical use of psilocybin-assisted psychotherapy (PAP) in adults living with depression.
Abstract Fifty-one cancer patients with symptoms of depression and anxiety were enrolled in a randomized, double-blind, crossover trial using low-dose psilocybin (placebo) and high-dose psilocybin (intervention group) combined with psychotherapy with 5 weeks between dosing sessions and at 6-month follow-up. Participants in the intervention group had large decreases in clinician- and self-rated...
Nasal esketamine has demonstrated efficacy in the management of treatment-resistant depression and psychiatric emergency due to major depression. This study investigates acceptance and awareness of esketamine as a depression treatment option, focusing on factors that influence patients' acceptance, including adherence to current medication regimens, regardless of prior esketamine exposure. This...
Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May 2025. Eligible...
Depression affects approximately 5.7% of adults worldwide, and around one-third of these individuals develop treatment-resistant depression (TRD). Intravenous (IV) ketamine and esketamine (administered IV or intranasally (IN)) are novel treatment options for TRD; however, only IN esketamine currently holds FDA approval. Compare the acute effectiveness of IV ketamine with esketamine (IV or IN)...
Intravenous ketamine is effective in treatment-resistant bipolar depression (TRBD) with dosing typically based on actual body weight (ABW). This study examined whether alternative normalization formulas are associated with treatment response. A retrospective exploratory analysis of a naturalistic registry for short-term ketamine use. A total of 22 TRBD inpatients received short-term intravenous...
Journal of Psychiatric Research2025Carolina Mariño-narvaez, Borja Romero-Gonzalez, Jose A Puertas-Gonzalez et al.7 citations
Hospital staff have experienced an increase in psychopathological symptoms such as anxiety or depression during the COVID-19 pandemic. Thus, the aims of the present research were, firstly, to study the effectiveness of the Mindfulness-Based Stress Reduction Program in reducing psychopathological symptoms in hospital staff during the COVID-19 pandemic, as well as, its effectiveness in increasing...
Female sex workers (FSW) living with HIV experience greater depression and worse HIV outcomes than people living with HIV (PLHIV) overall. Mindfulness is related to lower depression and higher ART adherence in PLHIV. Few studies have assessed these relationships among FSW, especially longitudinally. This study assessed the temporal relationship between mindfulness, mental health and HIV...
Objective: This study compared the long-term effects of a mindful compassion program on improving depression in lung cancer patients, both in patient-caregiver dyads and in patient-only groups, and examined the moderating roles of anxiety and quality of life (QOL). Method: Participants consisted of 56 dyads, who were randomly assigned to either the dyadic or patient-only groups. Data collection...
Within mindfulness-based programs (MBPs), mixed results have been found for the role of childhood trauma as a moderator of depression outcomes. Furthermore, childhood trauma and PTSD symptoms have been identified as possible risk factors for the occurrence of meditation-related adverse effects (MRAE). The present research examined multiple forms of childhood trauma and PTSD symptoms as...